Galectin Therapeutics Stock Buy Hold or Sell Recommendation
| GALT Stock | USD 2.89 0.05 1.76% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Galectin Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Galectin Therapeutics given historical horizon and risk tolerance towards Galectin Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Galectin Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Galectin Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide. Note, we conduct extensive research on individual companies such as Galectin and provide practical buy, sell, or hold advice based on investors' constraints. Galectin Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Galectin |
Execute Galectin Therapeutics Buy or Sell Advice
The Galectin recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Galectin Therapeutics. Macroaxis does not own or have any residual interests in Galectin Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Galectin Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Galectin Therapeutics Trading Alerts and Improvement Suggestions
| Galectin Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (41.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galectin Therapeutics currently holds about 15.83 M in cash with (32.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. | |
| Galectin Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: StockNews.com Upgrades Galectin Therapeutics to Hold - MarketBeat |
Galectin Therapeutics Returns Distribution Density
The distribution of Galectin Therapeutics' historical returns is an attempt to chart the uncertainty of Galectin Therapeutics' future price movements. The chart of the probability distribution of Galectin Therapeutics daily returns describes the distribution of returns around its average expected value. We use Galectin Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Galectin Therapeutics returns is essential to provide solid investment advice for Galectin Therapeutics.
| Mean Return | 0.06 | Value At Risk | -5.17 | Potential Upside | 5.63 | Standard Deviation | 3.10 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Galectin Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Galectin Stock Institutional Investors
The Galectin Therapeutics' institutional investors refer to entities that pool money to purchase Galectin Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Susquehanna International Group, Llp | 2024-06-30 | 202.3 K | Cutter & Co Brokerage, Inc. | 2024-09-30 | 115.5 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 114.7 K | Sanctuary Advisors, Llc | 2024-06-30 | 100.7 K | Squarepoint Ops Llc | 2024-06-30 | 84.1 K | Lpl Financial Corp | 2024-09-30 | 81.9 K | Charles Schwab Investment Management Inc | 2024-09-30 | 65.1 K | Bank Of New York Mellon Corp | 2024-06-30 | 64.4 K | Retirement Guys Formula Llc | 2024-09-30 | 63.8 K | Vanguard Group Inc | 2024-09-30 | 2.1 M | Blackrock Inc | 2024-06-30 | 1.6 M |
Galectin Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 39.2M | (20.3M) | 12.5M | (21.1M) | 7.1M | 7.4M | |
| Free Cash Flow | (10.8M) | (20.6M) | (24.3M) | (31.1M) | (33.0M) | (31.3M) | |
| Net Income | (13.3M) | (23.5M) | (30.5M) | (38.8M) | (41.1M) | (39.0M) | |
| End Period Cash Flow | 47.5M | 27.1M | 39.6M | 18.6M | 25.7M | 13.8M | |
| Dividends Paid | 394K | 137K | 171K | 97K | 120K | 114K | |
| Change To Netincome | 1.8M | 1.9M | 2.4M | 2.7M | 2.4M | 2.3M |
Galectin Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Galectin Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Galectin Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Galectin stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.17 | |
β | Beta against Dow Jones | 1.76 | |
σ | Overall volatility | 2.97 | |
Ir | Information ratio | -0.02 |
Galectin Therapeutics Volatility Alert
Galectin Therapeutics currently demonstrates below-average downside deviation. It has Information Ratio of -0.02 and Jensen Alpha of -0.17. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Galectin Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Galectin Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Galectin Therapeutics Fundamentals Vs Peers
Comparing Galectin Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Galectin Therapeutics' direct or indirect competition across all of the common fundamentals between Galectin Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Galectin Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Galectin Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Galectin Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Galectin Therapeutics to competition |
| Fundamentals | Galectin Therapeutics | Peer Average |
| Return On Equity | -37.28 | -0.31 |
| Return On Asset | -1.04 | -0.14 |
| Current Valuation | 257.68 M | 16.62 B |
| Shares Outstanding | 62.76 M | 571.82 M |
| Shares Owned By Insiders | 30.95 % | 10.09 % |
| Shares Owned By Institutions | 15.77 % | 39.21 % |
| Number Of Shares Shorted | 5.7 M | 4.71 M |
| Price To Earning | (4.21) X | 28.72 X |
| Price To Book | 207.70 X | 9.51 X |
| EBITDA | (202 K) | 3.9 B |
| Net Income | (41.07 M) | 570.98 M |
| Cash And Equivalents | 15.83 M | 2.7 B |
| Cash Per Share | 0.27 X | 5.01 X |
| Total Debt | 71.81 M | 5.32 B |
| Current Ratio | 1.79 X | 2.16 X |
| Book Value Per Share | (1.01) X | 1.93 K |
| Cash Flow From Operations | (32.97 M) | 971.22 M |
| Short Ratio | 42.37 X | 4.00 X |
| Earnings Per Share | (0.73) X | 3.12 X |
| Target Price | 11.0 | |
| Number Of Employees | 14 | 18.84 K |
| Beta | 0.63 | -0.15 |
| Market Capitalization | 181.38 M | 19.03 B |
| Total Asset | 28.2 M | 29.47 B |
| Retained Earnings | (354.37 M) | 9.33 B |
| Working Capital | 12.03 M | 1.48 B |
| Current Asset | 26.4 M | 9.34 B |
| Current Liabilities | 1.36 M | 7.9 B |
| Net Asset | 28.2 M |
Note: Acquisition by Joel Lewis of 11606 shares of Galectin Therapeutics at 1.66 subject to Rule 16b-3 [view details]
Galectin Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Galectin . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Galectin Therapeutics Buy or Sell Advice
When is the right time to buy or sell Galectin Therapeutics? Buying financial instruments such as Galectin Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Galectin Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Israel Wall Street Thematic Idea Now
Israel Wall Street
Cross-sector collection of best publicly traded Israel entities that are expected to continue growing. The Israel Wall Street theme has 71 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Israel Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.